paclitaxel has been researched along with Dysplastic Nevus Syndrome, Hereditary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X | 1 |
| Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y | 1 |
| Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Lan, S; Wu, D; Zhang, Y | 1 |
| Chau, E; Frieboes, HB; Godin, B; Goodin, DA; Tiwari, A | 1 |
| Dang, W; He, J; Jia, B; Jia, X; Li, H; Li, Z; Liu, Z; Xing, B; Yu, C; Zhang, Y | 1 |
| Arrowsmith, ER; Hainsworth, JD; Hauke, RJ; Infante, JR; Rubin, MS; Shih, KC | 1 |
1 review(s) available for paclitaxel and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Topics: Albumins; Angiogenesis Inhibitors; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Tumor Microenvironment | 2022 |
1 trial(s) available for paclitaxel and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Paclitaxel; Sirolimus; Skin Neoplasms; Treatment Outcome | 2013 |
5 other study(ies) available for paclitaxel and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment | 2022 |
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment | 2022 |
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids | 2022 |
Multiple breast cancer liver metastases response to macrophage-delivered nanotherapy evaluated via a 3D continuum model.
Topics: Animals; Liver Neoplasms; Macrophages; Melanoma, Cutaneous Malignant; Mice; Mice, Inbred BALB C; Paclitaxel; Tumor Microenvironment | 2023 |
Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer.
Topics: Breast Neoplasms; Cell Nucleus; Female; Humans; Lipids; Melanoma, Cutaneous Malignant; Nanostructures; Paclitaxel | 2023 |